Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402558 | 0.96 | CTSB (0.33) | CTSBPPP3CBELANEKCNH2 | |
| SCHEMBL13437245 | 0.92 | CTSB (0.30) | CTSBPPP3CB | |
| SCHEMBL8203717 | 0.84 | CTSB (0.36) | CTSBPPP3CBELANEKCNH2HTR3E | |
| SCHEMBL20292518 | 0.81 | PDE4B (0.33) | CTSBPPP3CB | |
| SCHEMBL15397439 | 0.81 | PDE4B (0.33) | CTSBPPP3CB | |
| SCHEMBL2754150 | 0.81 | AAK1 (0.38) | CTSBPPP3CBELANEKCNH2 | |
| SCHEMBL8203062 | 0.80 | CTSB (0.35) | CTSBPPP3CBELANEKCNH2HTR3E | |
| SCHEMBL3496077 | 0.79 | STING1 (0.35) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1072404 | 0.77 | PDE4B (0.33) | CTSBPPP3CB | |
| Hydrochloric Acid SCHEMBL2754129 | 0.76 | SRD5A2 (0.33) | CTSBPPP3CBHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309540-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | CTSB 69/4885PPP3CB 250/4885ELANE 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.